Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New program aims to cut HIV risk by fighting stigma for drug users

NCT ID NCT07541131

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a program called LIFT to help people who inject drugs in Kyrgyzstan face less stigma and lower their risk of HIV. About 80 participants will join peer-led group sessions to build support and learn how to use HIV prevention services. The goal is to see if the program reduces stigma and increases use of HIV prevention tools like PrEP and medication for opioid use disorder.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible PWID will meet the following inclusion criteria: 1. reports injecting drugs or using drugs with someone who was injecting in the past 12 months before enrollment, 2. is currently using illicit drugs (salts, synthetics, pharmaceuticals or opioids) including poly drug use, 3. ≥ 18 years old, 4. live in one of the two eligible districts 5. report no intentions to move from Bishkek in the next 18 months, 6. baseline rapid HIV test confirming HIV-negative status, and 7. agree to participate in all intervention and assessment activities. Eligible MMT Staff participants inclusion criteria: All clinical, administrative, and support staff at our two clinical MMT sites and implementation sites are eligible to participate. Inclusion criteria are: 1. ≥ 18 years old, 2. work in one of the eligible clinics, and 3. agree to participate in all intervention and assessment activities. Exclusion Criteria: * PWID Exclusion criteria are: 1. initiated injection drug use in the past 6 months, 2. report not currently using illicit drugs, 3. are \< 18 years old, 4. live outside the two eligible districts, 5. intend to move outside Bishkek in the next 18 months, 6. do not agree to participate in all community-level intervention activities (i.e., five peer-led group sessions, four survey assessments over 18 months), or are confirmed to be living with HIV by self-report or baseline rapid test. Note, to protect against unintended HIV status disclosure, PWID who are living with HIV (PWID-HIV) and who meet all other inclusion criteria will be given the option to participate in all study activities. However, PWID-HIV will not be included in our analytic sample of 68 PWID. Study staff will screen all potentially eligible PWID to confirm eligibility, schedule the baseline assessment, and confirmatory rapid HIV test before randomization, with an interviewer not affiliated with LIFT intervention activities.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug abuse illicit are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Public Foundation Den Sooluk Nuru

    Bishkek, Kyrgyzstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.